[Myelin Oligodendrocyte Glycoprotein Antibody Associated Disorders]

Brain Nerve. 2023 Jun;75(6):711-719. doi: 10.11477/mf.1416202406.
[Article in Japanese]

Abstract

The antibody against myelin oligodendrocyte glycoprotein (MOG) has been identified for its association with several clinical phenotypes including acute or multiphasic disseminated encephalomyelitis, optic neuritis, NMOSD, and brainstem or cerebral cortical encephalomyelitis, and now generally called MOG associated disorders (MOGAD). Recent brain-biopsied MOG-antibody-positive case reports have suggested the dominance of humoral immunity, and the humoral and cellular immune responses against MOG is elucidated to develop perivenous inflammatory demyelination. In this review, we will focus on the clinical, pathological, and treatment strategies for MOG-antibody-related diseases.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Autoantibodies
  • Brain
  • Encephalomyelitis*
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein
  • Optic Neuritis*

Substances

  • Myelin-Oligodendrocyte Glycoprotein
  • Autoantibodies